Literature DB >> 3348672

Acrocyanosis due to imipramine.

R P Anderson1, B A Morris.   

Abstract

An 11 year old girl who was being treated for enuresis with imipramine developed acrocyanosis of the hands and feet. All biochemical and haematological investigations gave normal results. When imipramine was stopped the girl recovered within three days.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3348672      PMCID： PMC1778745          DOI： 10.1136/adc.63.2.204

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN： 0003-9888            Impact factor:   3.791


  3 in total

1.  Raynaud's disease.

Authors:  E C Burns; D B Dunger; M J Dillon
Journal:  Arch Dis Child       Date:  1985-06       Impact factor: 3.791

2.  On the nature of Raynaud's phenomenon: the role of histamine.

Authors:  K Lafferty; J C De Trafford; V C Roberts; L T Cotton
Journal:  Lancet       Date:  1983-08-06       Impact factor: 79.321

3.  Imipramine-induced vasospasm: a case report.

Authors:  P S Appelbaum; W Kapoor
Journal:  Am J Psychiatry       Date:  1983-07       Impact factor: 18.112
  3 in total
  5 in total

1.  Signal that reboxetine use is linked with symptoms of peripheral ischaemia (Raynaud's syndrome).

Authors:  David W J Clark; Ana-Maria Correa-Nunes; I Ralph Edwards
Journal:  Eur J Clin Pharmacol       Date:  2003-05-17       Impact factor: 2.953

Review 2.  Acrocyanosis: the Flying Dutchman.

Authors:  Andrew K Kurklinsky; Virginia M Miller; Thom W Rooke
Journal:  Vasc Med       Date:  2011-03-22       Impact factor: 3.239

Review 3.  Drug therapy for nocturnal enuresis. Current treatment recommendations.

Authors:  K Miller; B Atkin; M L Moody
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

Review 4.  Nocturnal enuresis.

Authors:  U S Alon
Journal:  Pediatr Nephrol       Date:  1995-02       Impact factor: 3.714

5.  Acrocyanosis: an overview.

Authors:  Sudip Das; Arunasis Maiti
Journal:  Indian J Dermatol       Date:  2013-11       Impact factor: 1.494
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.